NASDAQ · Biotechnology
Codexis, Inc. (CDXS) Stock
$1.41
+3.68%
NASDAQ: CDXS
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
GlobeNewswire · May 20, 2026
Spotlight On Promising Penny Stocks For May 2026
Simply Wall St. · May 11, 2026
Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58
Simply Wall St. · May 11, 2026
Codexis (CDXS) Q1 2026 Earnings Transcript
Motley Fool · May 8, 2026
Codexis, Inc. Q1 2026 Earnings Call Summary
Moby · May 8, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held7.41%
Institutions Held74.95%
Institutions Float Held80.95%
Peer Comparison
About Codexis, Inc.
Codexis, Inc. is led by CEO Alison Moore, employs 188 people, headquartered in US, publicly traded since 2010.
Codexis, Inc. (CDXS) stock trades at $1.41 with a market capitalization of $151.66M. The stock is valued at a price-to-earnings (P/E) ratio of -4.05, price-to-book of 3.76, price-to-sales of 1.88. Over the past 52 weeks the stock has ranged between $0.96 and $2.98, and currently trades 52.7% below its 52-week high.
On profitability, Codexis, Inc. generates a return on equity (ROE) of -74.36%, return on capital employed of -25.12%, an operating margin of -54.29%, a net profit margin of -39.55%.